Business

Roche buys rights to Chinese cancer-drug portfolio for $510 million

Roche is paying $510 million for global rights to a portfolio of antibody-drug conjugates developed by China’s Hansoh Pharma. The cancer treatments combine antibodies with chemotherapy molecules, with Roche taking over development after the first clinical phase.